StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.92−0.81 (-1.85%)

Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –

Rigel Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Rigel Pharmaceuticals's pe ratio was 2.8× on Nov 11, 2026, against 8.2× a year earlier. Over the last 3 years it ranged from 1.4× to 131.5×, with a median of 9.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.8×−4.2
2025Dec 31, 20256.9×−73.2
2024Dec 31, 202480.1×+66.2
2012Feb 29, 201213.9×+2.9
2011Dec 30, 201111.0×–

More Rigel Pharmaceuticals figures

See a number that looks wrong?